Capricor Therapeutics Inc Share Price Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 243M 210M 197M 180M 338M 23.14B 343M 2.32B 906M 11.59B 911M 891M 38.64B | P/E 2026 * |
-2.96x | P/E 2027 * | -3x |
|---|---|---|---|---|---|
| Enterprise Value | 243M 210M 197M 180M 338M 23.14B 343M 2.32B 906M 11.59B 911M 891M 38.64B | EV / Sales 2026 * |
3.75x | EV / Sales 2027 * | 5.02x |
| Free-Float |
90.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 19/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 31/12/2017 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 31/10/2013 |
David Musket
BRD | Director/Board Member | 68 | 19/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 19/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 243M | |
| -0.73% | +7.82% | +73.81% | +102.34% | 70.1B | |
| -0.58% | +0.27% | +37.22% | +65.35% | 54.93B | |
| -1.57% | -0.94% | +6.87% | +488.83% | 28.89B | |
| +0.04% | +10.49% | +48.44% | +7.45% | 23.9B | |
| -0.12% | +1.83% | -17.67% | -13.58% | 23.3B | |
| -1.37% | +7.87% | +251.71% | +464.53% | 18.41B | |
| -1.13% | +7.57% | +40.45% | -20.36% | 18.77B | |
| -0.57% | +3.44% | +25.60% | +619.86% | 16.1B | |
| -0.48% | -3.20% | +31.28% | +134.91% | 12.48B | |
| Average | +0.28% | +8.38% | +55.30% | +205.48% | 29.65B | |
| Weighted average by Cap. | -0.77% | +9.43% | +53.80% | +167.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 64.76M 56.11M 52.57M 47.95M 90.14M 6.18B 91.53M 618M 242M 3.09B 243M 238M 10.31B | 48.38M 41.91M 39.27M 35.82M 67.34M 4.61B 68.38M 462M 181M 2.31B 182M 178M 7.7B |
| Net income | -82.36M -71.36M -66.86M -60.98M -115M -7.86B -116M -786M -307M -3.93B -309M -303M -13.12B | -83.73M -72.54M -67.97M -61.99M -117M -7.99B -118M -799M -312M -4B -314M -308M -13.33B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
